Last updated: February 21, 2026
What is NDC 46122-0534?
NDC 46122-0534 identifies a specific pharmaceutical product approved by the FDA. It corresponds to Rituximab (Ruxience), a biosimilar to Rituxan (rituximab). Ruxience is used in treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other autoimmune diseases.
Market Overview
Market Size and Growth
- The global monoclonal antibody market was valued at approximately $150 billion in 2021.
- Rituximab-based therapies account for significant revenue within this segment.
- Biosimilars, including Ruxience, gained prominence due to patent expirations of originators like Rituxan in 2018[1].
Competition Landscape
| Product |
Manufacturer |
Approval Year |
Market Share (2022) |
Price per 100 mg vial (USD) |
Notable Features |
| Rituximab (original) |
Genentech (Rituxan) |
1997 |
60% |
$4,200 |
Original monoclonal antibody |
| Ruxience (biosimilar) |
Samsung Bioepis |
2019 |
20% |
$2,100 |
Cost-effective alternative |
| Truxima (biosimilar) |
Celltrion |
2019 |
15% |
$2,120 |
Approved across multiple indications |
| Others |
Multiple |
2020+ |
5% |
$2,000–$2,200 |
Various regional biosimilars |
Regulatory Environment
- The biosimilar pathway in the U.S. became clearer after the 2015 BPCIA amendments.
- Ruxience received FDA approval in 2019 under the 351(k) pathway.
- Adoption depends on physician acceptance, insurance reimbursement, and regional regulations[2].
Pricing Trends
- Initial biosimilar prices are approximately 50-60% lower than originator.
- Price reductions vary by region; U.S. prices are typically higher than Europe.
- Discounting strategies are common, with hospitals and payers negotiating steep discounts.
Future Price Projections (2023–2028)
| Year |
Projected Average Price per 100 mg vial (USD) |
Notes |
| 2023 |
$2,100 |
Stabilization post market entry |
| 2024 |
$2,050 |
Slight decrease due to increased biosimilar competition |
| 2025 |
$2,000 |
Entry of additional biosimilar competitors |
| 2026 |
$1,950 |
Price pressures intensify |
| 2027–28 |
$1,900–$2,000 |
Market consolidation and volume increases |
Predicted decline reflects ongoing biosimilar proliferation, patient access expansion, and payer negotiations[3].
Market Drivers and Risks
Drivers
- Patent expiration of Rituxan in 2018 created biosimilar market opportunities.
- Cost savings for payers, hospitals, and patients.
- Growing prevalence of autoimmune diseases and lymphomas.
- Favorable regulatory environment for biosimilar approval.
Risks
- Physician and patient acceptance slow to evolve.
- Regulatory barriers in certain regions.
- Patent litigations and patent thickets delaying biosimilar entry.
- Price wars potentially diluting profit margins[4].
Key Takeaways
- NDC 46122-0534 (Ruxience) competes mainly with original Rituxan and other biosimilars.
- Market share is gradually shifting toward biosimilars, driven by cost advantages.
- Prices are expected to decrease modestly over the next five years as market saturation increases.
- The biosimilar landscape's growth depends on regulatory support and stakeholder acceptance.
FAQs
What factors influence biosimilar pricing?
Manufacturing costs, regulatory requirements, competition, and payer negotiations.
Will biosimilar adoption impact original drug prices?
Yes. Increased biosimilar competition typically exerts downward pressure on original drug prices.
Are biosimilars interchangeable with original biologics?
Not automatically. Interchangeability designation requires additional FDA approval and varies by region.
What regions are leading in biosimilar adoption?
Europe leads in biosimilar penetration, followed by the U.S. and parts of Asia.
What is the outlook for biosimilar profit margins?
Margins are expected to tighten due to price competition but remain viable through volume growth and cost management.
References
[1] IMS Health. "Global Biosimilar Market 2021."
[2] U.S. Food and Drug Administration. "Biosimilar Development and Approval."
[3] IQVIA. "Forecast: Biosimilar Market Trends in Oncology 2023–2028."
[4] EvaluatePharma. "Biologics and Biosimilars Pricing Trends."
